Anup Tiwari
Humans, mice, and other mammals express CD47 as a "marker of self" on the surface of every cell to prevent the phagocytic death of healthy cells by connecting with signal regulating protein on macrophages and dendritic cells and conveying a "don't eat me" signal. Unfortunately, a variety of cancer cells use this "don't eat me" signal to their advantage by overexpressing CD47 on their surface in order to circumvent immune surveillance and macrophage detection. As a result, blocking the CD47-SIRP axis may be a promising therapeutic target for the treatment of cancer. However, because to the broad expression of CD47 in normal tissues, CD47-targeted medicines can most likely result in major side effects including anaemia; hence, the precise administration of CD47-targeted therapeutics is essential. Contribute to enhancing clinical effectiveness and minimising negative effects. The "don't eat me" signal can also be used to create anti-phagocytic medication delivery systems that will lengthen blood circulation times and increase tumour site accumulation. The CD47-SIRP axis has two components that are the subject of this review: the precise delivery of CD47-targeted medicines by well-designed delivery systems, and the thoughtful design of CD47-based anti-phagocytic drug delivery systems.
KeywordsCD47-SIRPα axis; Drug delivery systems; Immunotherapy; Anti phagocytic
English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi